DR. AISHWARYA JOSHI

DR. RAMESH VENKATESH, DR. CHAITRA JAYADEV

Abstract

An interventional study where 58 adults with first episode of unilateral acute CSCR having symptoms for <12 weeks with no features of chronicity were divided into treatment [Tab. Eplerenone 50mg/day for min 1 month] and observation groups of 29 eyes each. Vision, SRF height and subfoveal choroidal thickness (SFCT) was checked at 1,2 and 3month visits in both eyes of each group. Vision improvement to 6/6 was seen in 92%, 100% and 100% cases in treatment group and 74%, 86% and 100% in control group at each visit respectively. Total SRF resolution in treatment wing was seen in 45%, 55%, and 62% cases at each month while it was 10%, 21% and 31% at each month in observation group. SRF (p<0.001) and SFCT (p<0.001) reduction was noted in the affected eye of both groups. SFCT reduced in the fellow eye after treatment (p=0.005) compared to observation group (p=0.276). Thus, oral eplerenone achieves faster SRF resolution and vision improvement in acute CSCR with benefits also in the fellow eye.